Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants

NCT05630326 | Completed DMC

• 1 other identifier: MRC-01-22-158
• Study Type: observational
• Target: 5,600
• Locations: 1 country
• Sites: 1

Brief Summary

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli. Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Conditions

Renal Insufficiency

Keywords

Chronic Kidney Diseases; Acute Kidney Injury; UTIs in infants; ESBL UTIs; chronic renal failure; UTIs with COVID-19; ESBL organisms with COVID-19

Outcome Measures

Primary Outcomes (1)

• Assessment risk factors , prevalence, and the relation between ESBL UTI and COVID-19 infection of all infants with ESBL- UTIs

  1year

Study Arms (4)

ESBL UTI

all infants with UTIs caused by ESBL producing organisms

Other: comparing, prevalence

Non-ESBL UTI

all infants with UTIs caused by non-ESBL producing organisms

Other: assessment

ESBL UTI with COVID-19

all infants with UTIs caused by ESBL producing organisms with COVID-19 infection

Other: association

ESBL UTI without COVID-19

all infants with UTIs caused by ESBL producing organisms without COVID-19 infection

Other: evaluation

Interventions

comparing, prevalence OTHER

Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.

Also known as: Data on clinical and laboratory findings are reviewed from medical records for details

ESBL UTI

assessment OTHER

comparing infants with UTIs caused by ESBL organism, or non ESBL organism.

Non-ESBL UTI

association OTHER

comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

ESBL UTI with COVID-19

evaluation OTHER

comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

ESBL UTI without COVID-19

Eligibility Criteria

• Age: Up to 1 Year
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

This retrospective review of electronic medical records from the pediatric division, Hamad General hospital in Doha, Qatar, will include all treated infants (0-1 years) who were diagnosed with UTI (Approximately 300 patients) between January 1, 2015, to january 1, 2022. Data collection will be done by co-investigators for all participants.

You may qualify if:

• All infants with UTIs who had been treated

You may not qualify if:

• Patient with a mixed urine culture.

Sponsors & Collaborators

• Hamad Medical Corporation: lead

Study Sites (1)

Hamad Medical Corporation

Doha, Qatar

Location

MeSH Terms

Conditions

Renal Insufficiency; Renal Insufficiency, Chronic; Acute Kidney Injury; Kidney Failure, Chronic

Interventions

Prevalence; Restraint, Physical; Association

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Morbidity; Vital Statistics; Data Collection; Epidemiologic Methods; Investigative Techniques; Demography; Population Characteristics; Epidemiologic Measurements; Public Health; Environment and Public Health; Behavior Control; Therapeutics; Immobilization; Psychotherapeutic Processes; Psychotherapy; Behavioral Disciplines and Activities

Study Officials

• Mahmoud Alhandi Omar Helal

  Hamad Medical Corporation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2022
• First Posted: November 29, 2022
• Study Start: March 1, 2023
• Primary Completion: July 1, 2023
• Study Completion: July 20, 2023
• Last Updated: July 27, 2023

Record last verified: 2022-04

Locations

QA (1)